- Home
- SISI vs SLXN Comparison
SISI vs SLXN Comparison
Compare SISI & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- SLXN
- Stock Information
- Founded
- SISI 1997
- SLXN 2008
- Country
- SISI China
- SLXN Israel
- Employees
- SISI N/A
- SLXN N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- SLXN
- Sector
- SISI Health Care
- SLXN
- Exchange
- SISI Nasdaq
- SLXN NYSE
- Market Cap
- SISI 5.9M
- SLXN 5.2M
- IPO Year
- SISI 2016
- SLXN N/A
- Fundamental
- Price
- SISI $2.23
- SLXN $2.53
- Analyst Decision
- SISI
- SLXN Strong Buy
- Analyst Count
- SISI 0
- SLXN 1
- Target Price
- SISI N/A
- SLXN $1.00
- AVG Volume (30 Days)
- SISI 231.7K
- SLXN 1.0M
- Earning Date
- SISI 02-06-2025
- SLXN 02-21-2025
- Dividend Yield
- SISI N/A
- SLXN N/A
- EPS Growth
- SISI N/A
- SLXN N/A
- EPS
- SISI N/A
- SLXN N/A
- Revenue
- SISI $10,330,284.00
- SLXN N/A
- Revenue This Year
- SISI N/A
- SLXN N/A
- Revenue Next Year
- SISI N/A
- SLXN N/A
- P/E Ratio
- SISI N/A
- SLXN N/A
- Revenue Growth
- SISI 370.34
- SLXN N/A
- 52 Week Low
- SISI $1.95
- SLXN $0.21
- 52 Week High
- SISI $117.65
- SLXN $13.56
- Technical
- Relative Strength Index (RSI)
- SISI 41.72
- SLXN N/A
- Support Level
- SISI $1.95
- SLXN N/A
- Resistance Level
- SISI $2.48
- SLXN N/A
- Average True Range (ATR)
- SISI 0.22
- SLXN 0.00
- MACD
- SISI 0.06
- SLXN 0.00
- Stochastic Oscillator
- SISI 35.62
- SLXN 0.00
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.